Iovance Biotherapeutics
Mr. Maynard is currently the Chief Financial Officer of Paulus Holdings Ltd. d/b/a LetsGetChecked. Mr. Maynard previously was the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company. Mr. Maynard has served in various executive roles at Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company, including ten years as Chief Financial Officer. Prior to joining Rigel, Mr. Maynard served as Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, and Controller of General Magic, Inc. Mr. Maynard has held various positions at Siliconix, Inc., including Senior Finance Manager. Mr. Maynard previously worked at Ernst & Young LLP. Mr. Maynard holds a B.S. in Commerce – Accounting from Santa Clara University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Iovance Biotherapeutics
6 followers
Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.